- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04285866
Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy. (S-REAL)
Spanish Real World Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy.
This is a non-interventional, observational, multicentre, one-arm, non-comparative, and retrospective study.
The study is based on the collection of data about the patients treated with Durvalumab after chemoraditherapy in the real world. The patients participating in this non-interventional study will not receive treatment in relation to the study. The primary objective is to assess affectiveness of durvalumab in patients treated in real-life settings by evaluating Progression Free Survival.
Study Overview
Detailed Description
Lung Cancer represent approximately 13% of total cancer diagnoses worldwide and continues to be the leading cause of cancer-related mortality. Stage III represents between 25-30% of NSCLC and the majority of them are unresectable. The standard treatment in unresectable patients was chemoradiotherapy consurrently if possible.
The PACIFIC study is a phase III study to evaluate the efficacy and safety of durvalumab as a sequential therapy concurrent platinum-based chemotherapy and thoracic RT. The study was positive for both primary endpoints progression-free survival and overall survival. After that, it was decided to open an early acces programme ti provide acces to durvalumab for patients with locally advanced, unresectable NSCLC (stage III) tho have not progressed following chemoradiation.
This observational study is based on the collection of data about the patients treated with Durvalumab after chemoraditherapy in the real world.
The study will include all patients who have participated in the EAP between 1 September 2017 up to 21 December 2018 and have received at least 1 dose of durvalumab.
The primary objective is to assess affectiveness of durvalumab in patients treated in real-life settings by evaluating Progression Free Survival. Other secondary objectives are:
To assess effectiveness of durvalumab in patients treated in real-life settings by evaluating 1-year survival rate, to describe adverse events of special interests, to stimate time and sites of disease progression or relapse in metastatic setting, to describe details on durvalumab treatment, to describe demographic and clinical characteristics of stage III unresectable NSCLC patients treated with Durvalumab, to describe previous chemoradiotherapy strategy, to describe the baseline staging status, to further assess subsequent treatments pattern at the time of disease progression including duration of therapy and type of therapy, and to explore healthcare resource utilization while on durvalumab treatment.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
A Coruña, Spain, 15006
- Hospital de A Coruña
-
Alicante, Spain, 03010
- Hospital General de Alicante
-
Barcelona, Spain, 08003
- Consorci Mar Parc de Salut de Barcelona
-
Córdoba, Spain, 14004
- Hospital Universitario Reina Sofia
-
Granada, Spain, 18016
- Hospital Universitario Clínico San Cecilio
-
Guadalajara, Spain, 19002
- Hospital Universitario de Guadalajara
-
Jaén, Spain, 23007
- Complejo Hospitalario de Jaén
-
Madrid, Spain, 28040
- Hospital Clinico San Carlos
-
Madrid, Spain, 28040
- Hospital Universitario Fundacion Jimenez Diaz
-
Madrid, Spain, 28034
- Hospital Ramón y Cajal
-
Madrid, Spain, 28007
- Hospital General Universitario Gregorio Maranon
-
Madrid, Spain, 28006
- Hospital La Princesa
-
Madrid, Spain, 28702
- Hospital Universitario Infanta Sofía
-
Madrid, Spain, 28050
- Hospital de Sanchinarro
-
Ourense, Spain, 32005
- Complexo Hospitalario de Ourense
-
Salamanca, Spain, 37007
- Hospital Clinico Universitario de Salamanca
-
Segovia, Spain, 40002
- Hospital General de Segovia
-
Sevilla, Spain, 41013
- Hospital Virgen del Rocio
-
Toledo, Spain, 45071
- Hospital Virgen De La Salud
-
Valencia, Spain, 46009
- Hospital Universitari I Politecnic La Fe
-
Valladolid, Spain, 47003
- Hospital Clínico Universitario de Valladolid
-
Zaragoza, Spain, 50009
- Hospital Clinico Lozano Blesa
-
Zaragoza, Spain, 50009
- Hospital Universitario Miguel Servet
-
-
A Coruña
-
Santiago De Compostela, A Coruña, Spain, 15706
- Hospital Clinico Universitario de Santiago
-
-
Asturias
-
Oviedo, Asturias, Spain, 33011
- Hospital Universitario Central de Asturias
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Hospital Universitari Germans Trias I Pujol
-
Granollers, Barcelona, Spain, 08402
- Hospital General de Granollers
-
Sabadell, Barcelona, Spain, 08208
- Corporació Sanitària Parc Taulí
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
- Hospital Marques de Valdecilla
-
-
Cataluña
-
Barcelona, Cataluña, Spain, 08041
- Hospital de la Santa Creu i Sant Pau
-
-
Gran Canaria
-
Las Palmas De Gran Canaria, Gran Canaria, Spain, 35016
- Hospital Universitario Insular de Gran Canaria
-
-
Illes Balears
-
Palma De Mallorca, Illes Balears, Spain, 07198
- Hospital Universitario Son Llatzer
-
-
Madrid
-
Alcorcón, Madrid, Spain, 28922
- Hospital Universitario Fundacion Alcorcon
-
-
Málaga
-
Marbella, Málaga, Spain, 29603
- Hospital Costa del Sol
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Clinica Universidad de Navarra
-
-
País Vasco
-
Donostia, País Vasco, Spain, 20014
- Hospital Universitario de Donostia
-
-
Tenerife
-
Santa Cruz de Tenerife, Tenerife, Spain, 38010
- Hospital Nuestra Senora de Candelaria
-
-
Valencia
-
Alzira, Valencia, Spain, 46600
- Hospital Universitario de La Ribera
-
-
Vizcaya
-
Bilbao, Vizcaya, Spain, 48013
- Hospital Universitario de Basurto
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients must have histologically or cytologically documented diagnosis of NSCLC with a locally advanced, or locally recurrent, unresectable (stage III) disease (according to American Joint Committee on Cancer [AJCC] lung cancer edition 7 or 8).
- Age ≥ 18 years at time of study Entry
- Patients must have been treated with chemotherapy and radiotherapy concurrently or sequentially and shown no progressive disease following chemoradiation
- Patients must have been enrolled in durvalumab EAPs between 1 September 2017 and 21 December 2018.
- Patients must have been treated with at least one dose of durvalumab within the EAP
- Alive patients must have signed, dated and IRB/EC-approved written informed consent* form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.
Exclusion Criteria:
- Alive patients who do not want to sign and date an IRB/IEC-approved written informed consent form.
- Patients who were accepted in the EAP, but did not receive treatment.
- Patients treated with durvalumab in clinical studies prior to the index date (first dose of durvalumab received within the EAP
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Durvalumab Group
Patients who have participated in the EAP between 1 September 2017 up to 21 December 2018 and have received at least 1 dose of durvalumab.
|
Durvalumab after chemoradiotherapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS)
Time Frame: From date of the first dose of durvalumab received (within the EAP) to the date of disease progression, death, or the end of follow-up, assessed up to 60 months
|
To assess effectiveness of durvalumab in patients treated in real-life settings by evaluating PFS
|
From date of the first dose of durvalumab received (within the EAP) to the date of disease progression, death, or the end of follow-up, assessed up to 60 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1-year survival rate
Time Frame: 1 year
|
To assess effectiveness of durvalumab in patients treated in real-life settings by evaluating 1-year survival rate.
|
1 year
|
To describe adverse events of special interest (AESIs)
Time Frame: From date of the first dose of durvalumab received (within the EAP) to the date of disease progression, death, or the end of follow-up, assessed up to 60 months
|
To describe AESIs leading to treatment temporary interruption or permanent discontinuation of durvalumab, or which require interventions of concomitant use of corticosteroids, immunosupressants and/or endocrine therapies.
|
From date of the first dose of durvalumab received (within the EAP) to the date of disease progression, death, or the end of follow-up, assessed up to 60 months
|
Time and site of disease progression or relapse
Time Frame: From date of the first dose of durvalumab received to the date of disease progression, assessed up to 60 months
|
To estimate time and sites of disease progression or relapse in metastatic setting.
|
From date of the first dose of durvalumab received to the date of disease progression, assessed up to 60 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Pilar Garrido, MD, Fundación GECP Investigator
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GECP 19/02_S-REAL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Cancer (SCLC)
-
AstraZenecaCompletedRefractory Solid Tumours | Relapsed Small Cell Lung Cancer (SCLC)United States, Canada
-
Kyowa Kirin Korea Co., Ltd.TerminatedPhase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma | Phase 2 Portion : Small Cell Lung Cancer(SCLC)Korea, Republic of
-
Genentech, Inc.Flatiron Health, Inc.; Foundation Medicine, Inc.CompletedNon-Small Cell Lung Cancer (NSCLC) | Small-Cell Lung Cancer (SCLC)United States
-
Stanford UniversityTerminatedLung Cancer | Mesothelioma | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer Small Cell Lung Cancer (SCLC)United States
-
Joel NealNektar TherapeuticsCompletedTumors Metastatic to Brain | Stage IV Non-small Cell Lung Cancer (NSCLC) | Recurrent Non-small Cell Lung Cancer (NSCLC) | Extensive-stage Small Cell Lung Cancer (SCLC) | Recurrent Small Cell Lung Cancer (SCLC) | Metastatic Breast Cancer (mBC)United States
-
Stanford UniversityThe American Association of Physicists in MedicineTerminatedPancreatic Cancer | Lung Cancer | Liver Cancer | Hepatobiliary Cancers | Hepatobiliary Cancers Liver | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer Small Cell Lung Cancer (SCLC) | Hepatobiliary Cancers Hepatocellular Carcinoma (Hepatoma) | Hepatobiliary Cancers Gallbladder | Hepatobiliary Cancers...United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...CompletedSCLC | Small-cell Lung Cancer | Small Cell Lung Cancer Limited StageUnited States
-
Bristol-Myers SquibbCompletedLung Cancer | Non-small Cell Lung Cancer NSCLC | Small Cell Lung Cancer SCLCChina
-
Haibo ZhangRecruitingSmall Cell Lung Cancer (SCLC)China
-
Giuseppe GiacconeMemorial Sloan Kettering Cancer Center; Vanderbilt UniversityTerminatedSmall Cell Lung Cancer ( SCLC )United States
Clinical Trials on Durvalumab
-
AstraZenecaKappa SantéRecruiting
-
Yonsei UniversityRecruitingPotentially Resectable Stage II/IIIa NSCLCKorea, Republic of
-
Academic Thoracic Oncology Medical Investigators...AstraZenecaCompletedNon-Small Cell Lung Cancer NSCLCUnited States
-
Yonsei UniversityCompleted
-
NSABP Foundation IncCompletedRectal CancerUnited States
-
Hark Kyun KimRecruiting
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
MedImmune LLCCompletedAdvanced Solid TumorsUnited States, France, Spain, Switzerland
-
MedImmune LLCCompletedStage III Non-small Cell Lung Cancer | UnresectableUnited States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
-
AstraZenecaCompleted